AI assistant
DIMERIX LIMITED — Capital/Financing Update 2009
Jun 30, 2009
64804_rns_2009-06-30_804707dd-b6d3-46a1-bf35-56a7e8d63067.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [228 x 83] intentionally omitted <==
1 July 2009
The Manager Company Announcements Platform ASX Limited
Dear Sir/Madam
Expiry of Options
Sun Biomedical Limited advises that 986,263 Options exercisable at 1.3 cents and expiring 30 June 2009 have lapsed.
For further information see www.sunbiomed.com or contact:
Jim Hallam Director Mobile: 0414 965 442
About Sun Biomedical Limited
Sun Biomedical Limited is a public company listed on the Australian Securities Exchange (ASX) under the symbol "SBN". SBN’s main business is its wholly owned subsidiary, Sun Biomedical Laboratories Inc. (SBL) which produces both urine and saliva based drugs of abuse testing devices at its main facility in Blackwood, New Jersey. SBL has established an industry benchmark with the most sensitive saliva drugs of abuse testing device available on the market today. SBL also has a portfolio of research into the use of saliva as a diagnostic medium for other disease states that provide the foundation for continued research and development and a broader portfolio of point of care testing devices.
For more information about Sun Biomedical Laboratories and its products, contact us at +1-888-440-8388 or visit www.sunbiomed.com.
Sun Biomedical Investor Communications Limited Computershare T: +61 1300 728 275 | F: +61 3 9473 2500 | ABN 18 001 285 230 E: [email protected]
ASX:SBN www.sunbiomed.com